SCHEMBL25100482

SCHEMBL25100482

CNC(=O)CNC(=O)CCCCCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 2/20 0.41
HPGD P15428 1/20 0.41
HDAC6 Q9UBN7 10/20 0.40
HDAC1 Q13547 9/20 0.40
HDAC4 P56524 7/20 0.40
HDAC7 Q8WUI4 7/20 0.40
HDAC2 Q92769 7/20 0.40
HDAC10 Q969S8 7/20 0.40
HDAC3 O15379 7/20 0.40
HDAC8 Q9BY41 7/20 0.40
HDAC11 Q96DB2 6/20 0.40
HDAC9 Q9UKV0 6/20 0.40
HDAC5 Q9UQL6 6/20 0.40
ALDH1A1 P00352 3/20 0.38
FOLH1 Q04609 2/20 0.36
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25748806 0.89 HDAC6 (0.41) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL25748809 0.89 HDAC6 (0.41) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL25964475 0.88 SMN1; SMN2 (0.44) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL23680206 0.87 SMN1; SMN2 (0.43) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL22064399 0.85 HDAC3 (0.36) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL20169738 0.85 HDAC3 (0.36) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL22688569 0.84 HDAC3 (0.38) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL26005517 0.84 SMN1; SMN2 (0.41) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL24341207 0.84 SMN1; SMN2 (0.41) SMN1; SMN2HTTHPGDHDAC6HDAC1
SCHEMBL15505722 0.83 HDAC3 (0.37) SMN1; SMN2HTTHPGDHDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11596693-B2 Antibody-drug conjugates and uses thereof MABPLEX INTERNATIONAL CO., LTD (CN) 2023-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11596693-B2 Antibody-drug conjugates and uses thereof DARS1, CD2, FCGR2A SMN1; SMN2 3752/4885HTT 2764/4885HPGD 3063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.